Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

Investing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Investing cash flow turns positive

Q2 FY2026 investing cash flow was $81.15M, compared with -$13.27M a year earlier. Trailing-twelve-month investing cash flow was $12.42M. Over 3 fiscal years it compounded at -18.5% a year.

Context

  • Investing cash flow amounted to 11.6% of revenue in FY2025, down 5.1 pp from a year earlier.
  • Investing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly investing cash flow holds near $81.15M or moves back toward the trailing-twelve-month quarterly average of $3.1M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$81.15M+548.9% QoQ
Last fiscal yearDec 2025
-$32.77M-183.5% YoY
LTMJun 2026
$12.42M-73.2% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+711.4%——
1 year-183.5%——
3-year CAGR-18.5%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(32.77M) USD
Year-over-year change
-183.5%

Investing Cash Flow vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's LTM Jun 2026 investing cash flow of $12.42M is the 9th largest of the 10 companies compared; the peer median is $12.86M.
  • Its year-over-year change of -73.2% is the 7th highest of 9, against a peer median of +124.8%.
  • Investing cash flow amounts to 4.0% of revenue for AUPH, versus a peer median of 1732.8%.
AUPH Competitors Peer median
Investing Cash Flow for AUPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TRAXFirst Tracks Biotherapeutics IncFY2025$228.03M +139.0%——
EVMNEvommune, Inc.LTM Mar 2026$214.17M ——2141.7%
BHVNBiohaven Ltd.LTM Jun 2026$211.26M +765.6%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$146.84M +221.8%——
ALMSAlumis Inc. Common StockLTM Jun 2026$97.94M -191.9%—1323.9%
ATTOAttovia Therapeutics, Inc.FY2025$73.46M +84.5%—5441.1%
VERAVera Therapeutics, Inc.LTM Jun 2026$45.47M +132.7%——
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$12.86M +116.9%——
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$12.42M -73.2%-18.5%4.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$1.69M -97.5%+56.5%20.2%
Peer median (excluding AUPH) $12.86M+124.8%+56.5%1732.8%

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(180.97M)(108.18M)(78.02M)5.75M287.2M
Depreciation & Amortization2.76M2.71M11.65M19.45M9.27M
Deferred Income Tax0000(176.19M)
Stock-Based Compensation31.24M32.3M45.31M31.6M14.68M
Change in Working Capital(21.63M)(6.82M)(5.61M)5.45M(8.78M)
Accounts Receivables(15.42M)1.93M(10.61M)(12.46M)(4.91M)
Inventory(5.64M)(9.07M)(15.87M)477K(6.46M)
Accounts Payables4.08M(792K)1.24M860K(1.87M)
Other Working Capital(4.65M)1.12M19.63M16.57M4.46M
Other Non-Cash Items10.9M462K(6.79M)(17.85M)9.49M
Operating Cash Flow(157.69M)(79.53M)(33.46M)44.39M135.66M
Capital Expenditures(1.5M)(292K)(718K)(281K)(252K)
Acquisitions (Net)(1.2M)0000
Purchases of Investments(438.96M)(523.99M)(523.5M)(545.83M)(526.65M)
Sales of Investments354.43M464.32M529.38M585.42M494.13M
Other Investing Activities(16.63M)(663K)(11.86M)(43K)0
Investing Cash Flow(103.87M)(60.63M)(6.71M)39.26M(32.77M)
Debt Repayment00(10.03M)(11.99M)(13.14M)
Common Stock Issued196.74M00014.95M
Common Stock Repurchased000(40.24M)(98.16M)
Dividends Paid00000
Other Financing Activities24.37M2.43M4.9M3.14M(9.76M)
Financing Cash Flow221.11M2.43M(5.13M)(49.09M)(106.11M)
Effect of Forex Changes00000
Net Change in Cash(40.45M)(137.73M)(45.3M)34.56M(3.22M)
Free Cash Flow(159.19M)(79.82M)(34.18M)44.11M135.41M

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.